logo

For the Inventor, By the Inventor

Lebanon, NH, United States of America

Adimab, LLC


USPTO Granted Patents = 52

% Expired Patents = 5.8


Trademarks = 8

Forward Citations = 162

Loading Chart...
Loading Chart...

75 inventors (with patents filed for the assignee):

goldMedal Laura M Walker (16 out of 24 patents)

silverMedal Michael Feldhaus (14 out of 30 patents)

bronzeMedal Maximiliano Vasquez (12 out of 69 patents)

4.  Bianka Prinz (10 out of 60 patents)

5.  Zhu Chen (8 out of 8 patents)

6.  Kenneth Ellsworth (8 out of 9 patents)

7.  James Milligan (8 out of 8 patents)

8.  Elizabeth Oldham (8 out of 8 patents)

9.  Dietmar Seiffert (8 out of 8 patents)

10.  K Dane Wittrup (8 out of 28 patents)

11.  Zachary A Bornholdt (7 out of 7 patents)

12.  Larry Zeitlin (7 out of 7 patents)

13.  Kartik Chandran (7 out of 20 patents)

14.  Eric Krauland (7 out of 20 patents)

15.  Anna Z Wec (7 out of 14 patents)


Core Competencies:
Monoclonal Antibodies
Polyclonal Antibodies
Antibody Libraries
Multispecific Antibodies
Neural Disease Immunotherapy
Anti-Coagulation Factor XI
Anti-Respiratory Syncytial Virus
Synthetic Antibody Libraries
Polyspecificity Reagents
Ebola Treatment
Affinity Maturation
Anti-IL-27 Antibodies

52 patents:

1. 12679892 - B7-H4 ANTIBODIES AND METHODS OF USE THEREOF (2026-07-14),
2. 12630624 - ANTI-IL-27 ANTIBODIES AND USES THEREOF (2026-05-19),
3. 12624105 - CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE (2026-05-12),
4. 12529164 - RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR (2026-01-20),
5. 12281156 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-04-21),
6. 12275800 - Anti-coagulation factor XI antibodies (2025-04-14),
7. 12258679 - Polyclonal mixtures of antibodies, and methods of making and using them (2025-03-25),
8. 12215141 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-02-04),
9. 12209117 - Monoclonal antibodies and cocktails for treatment of Ebola infections (2025-01-28),
10. 12181480 - Polyspecificity reagents, methods for their preparation and use (2024-12-31),
11. 12180299 - Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use (2024-12-31),
12. 12018403 - Antibody libraries (2024-06-25),
13. 11746160 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2023-09-05),
14. 11661460 - Anti-coagulation factor XI antibodies (2023-05-30),
15. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use (2023-01-03),
Adimab is a privately held biotechnology company focused on developing fully human monoclonal antibodies. The company has developed a proprietary yeast-based antibody discovery platform that enables rapid and efficient generation of therapeutic antibodies for a wide range of diseases. Adimab's technology has been utilized to discover and optimize antibody candidates for various partners in the pharmaceutical and biotech industry.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Adimab, LLC
52 Patents

#2 in Lebanon, NH

#50 in New Hampshire

#6,757 in US

#13,537 in the World

Lebanon, NH (US)
Lebanon, NH, United States of America

Adimab, LLC

Forward Citations = 162

75 inventors:

goldMedal Laura M Walker (16 out of 24 patents)

silverMedal Michael Feldhaus (14 out of 30 patents)

bronzeMedal Maximiliano Vasquez (12 out of 69 patents)

4.  Bianka Prinz (10 out of 60 patents)

5.  Zhu Chen (8 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…